Trials / Completed
CompletedNCT00761982
Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.
Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Hospital Universitario Central de Asturias · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to determine the safety and efficacy on an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute middle cerebral artery stroke.
Detailed description
The proposed trial will involve the recruitment of a total of 20 patients. The cells will be collected from ten subject recruited as cases, via bone marrow sampling. The aspirate will be centrifuged on a Ficoll density gradient to isolate mononuclear cells, which will be resuspended in heparinized isotonic saline for infusion into the area of the stroke intra-arterially using the middle cerebral artery. The investigators will monitor each case and control for a period of 6 months post-stem cell infusion. Initially, they will be subjected to a review after one month,three months and finally 6 months. Assessment of adverse events will be by physical examination and measurement of laboratory parameters. Assessment of efficacy will be by physical examination and the measurement of laboratory, CT and MRI parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Infusion on autologous CD34+ stem cells into middle cerebral artery | Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2008-09-30
- Last updated
- 2011-11-29
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00761982. Inclusion in this directory is not an endorsement.